Beta: Sign in
Shares outstandingAs of 2026-08-14 · filed common shares: 243.44M
Shares float: Sign in
Float %: Sign in
Insider ownershipDirectors and officers, from their latest Form 3/4/5 holding: 0.20%
Institutional ownership: Sign in
Short interestShare of shares outstanding, at settlement: 13.52%
Short ratioDays to cover, as published by FINRA: 1.64
Short volume (5D)Share of FINRA reporting-facility volume sold short, daily flow: 54.40%
Short volume (20D)Share of FINRA reporting-facility volume sold short, daily flow: 56.50%
Avg volume (10D)

See the full stock page

Prices, charts, ranges, valuation ratios, dividends, momentum and analyst estimates are licensed for signed-in members. A free account opens every stock, fund and crypto page.

Create free account

Source: SEC filings. Information and analytics, not investment advice.

Rev growth (fwd)

Avg volume (3 months)

Profitability

Gross marginFY Sep 25: 4.05%
Operating marginFY Sep 25: -4744.25%
Net margin: —
EBITDA marginFY Sep 25: -4735.97%
Return on equity: —
Return on assetsNet income (TTM to Jun 26) ÷ average total assets: -251.66%

Growth

Revenue growth (annual YoY): —
Revenue growth (latest qtr YoY): —
Revenue growth (fwd): Sign in
Net income growth (annual YoY): —
Net income growth (latest qtr YoY): —
EPS growth (fwd): Sign in
Net income growth (QoQ): —

Valuation

Market cap: Sign in
Enterprise value: Sign in
P/E: Sign in
P/E (fwd): Sign in
PEG: Sign in
PEG (fwd): Sign in
Price / book: Sign in
Price / sales

Price / operating cash flow

P/FCF

EV / revenue

EV / EBITDA

EPSDiluted, TTM to Jun 26

-0.70

EPS (fwd)

Financial health

Cash & equivalentsas of Jun 26: $11.24M
Total cash: Sign in
Total debtBorrowings + finance and operating lease liabilities, as of Jun 26: $204.14K
Debt / equityas of Jun 26: -1.96%
Current ratioas of Jun 26: 0.81
Quick ratio(Cash + marketable securities + receivables) ÷ current liabilities, as of Jun 26: 0.45
Operating cash flowTTM to Jun 26: -$56.15M
Free cash flow (nine months)Nine months: 2025-10-01 to 2026-06-30 · Not annualized: -$43.77M
TTM revenue / diluted share: —

OTLK stock Statistics — Outlook Therapeutics, Inc. filings, insiders & smart money · Instaport